Advances in male hormonal contraception

New male contraceptive options are urgently needed. Safe, effective and fully reversible methods of male contraception would be useful for monogamous couples who are trying to regulate their family size. In addition, an effective male hormonal contraceptive that could be implanted or injected as a long-acting formulation every 3-6 months would be useful in countries where limiting population growth has become a public policy imperative. Male hormonal contraception is based on the same principles as traditional oestrogen-progestin female oral contraceptives. Both spermatogenesis and ovulation are dependent upon normal secretion of the pituitary gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Exogenous gonadotropin-releasing hormone (GnRH) analogues and sex steroid hormones such as testosterone CO and progestins suppress gonadotropins and spermatogenesis. Two large multicentre trials demonstrated that weekly administration of high-dosage T was very effective in suppressing gonadotropins and spermatogenesis and conferred an overall contraceptive efficacy comparable to female oral contraceptives. Studies of combination regimens of lower-dosage T plus a progestin or a GnRH analogue have demonstrated greater suppression of spermatogenesis than the World Health Organization trials of high-dosage T. Most of these male hormonal contraceptives have been associated with modest weight gain and suppression of serum high-density cholesterol (HDL) levels. In this article, we review the new developments in male hormonal contraception.

[1]  A. Matsumoto,et al.  Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. , 2002, Journal of andrology.

[2]  N. Moeloek,et al.  Achieving azoospermia by injections of testosterone undecanoate only or combined with depot medroxyprogesterone acetate in Indonesian men , 2001 .

[3]  J. Greer,et al.  Pharmacological and endocrine characterization of A‐198401, an orally active GnRH antagonist, in intact and castrate male rat models , 2001 .

[4]  E. Nieschlag,et al.  Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. , 2001, Clinical endocrinology.

[5]  K. Herbst,et al.  Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. , 2000, Fertility and sterility.

[6]  H. Baker,et al.  Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. , 2000, Contraception.

[7]  A. von Eckardstein,et al.  Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo‐controlled feasability study for male contraception , 2000, Clinical endocrinology.

[8]  K. Sundaram,et al.  7alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy. , 2000, International journal of andrology.

[9]  P. Ho,et al.  Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. , 2000, Human reproduction.

[10]  M. Steiner Contraceptive effectiveness: what should the counseling message be? , 1999, JAMA.

[11]  D. Baird,et al.  7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. , 1999, The Journal of clinical endocrinology and metabolism.

[12]  W. Bremner,et al.  A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  A. Negro-Vilar Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.

[14]  J. Suvisaari,et al.  Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. , 1999, Human reproduction.

[15]  A. Matsumoto,et al.  A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. , 1999, Journal of andrology.

[16]  E. Nieschlag,et al.  Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. , 1999, European journal of endocrinology.

[17]  A. von Eckardstein,et al.  Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. , 1999, The Journal of clinical endocrinology and metabolism.

[18]  L. Hamann,et al.  Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). , 1999, Journal of medicinal chemistry.

[19]  A. Matsumoto,et al.  The therapeutic potential of testosterone patches. , 1998, Expert opinion on investigational drugs.

[20]  D. Cummings,et al.  Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. , 1998, The Journal of clinical endocrinology and metabolism.

[21]  W. Bremner,et al.  A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. , 1998, Journal of andrology.

[22]  S. Sasaki,et al.  Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. , 1998, Journal of medicinal chemistry.

[23]  R. Swerdloff,et al.  Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. , 1998, The Journal of clinical endocrinology and metabolism.

[24]  W. Bremner,et al.  Low dose of cyproterone acetate and testosterone enanthate for contraception in men. , 1998, Human reproduction.

[25]  J. Edwards,et al.  Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. , 1998, Journal of medicinal chemistry.

[26]  W. Bremner,et al.  An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. , 1997, Fertility and sterility.

[27]  A. Pollack,et al.  Results of a pilot study of the time to azoospermia after vasectomy in Mexico City. , 1997, Contraception.

[28]  J. Suvisaari,et al.  Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men. , 1997, Human reproduction.

[29]  David Handelsman,et al.  Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. , 1996, The Journal of clinical endocrinology and metabolism.

[30]  Contraceptive efficacy of testosterone‐induced azoospermia and oligozoospermia in normal men , 1996, Fertility and sterility.

[31]  W. Bremner,et al.  A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. , 1996, The Journal of clinical endocrinology and metabolism.

[32]  P. McDonough,et al.  Correction to "World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996;65:821-9." , 1996 .

[33]  R. Anderson,et al.  Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. , 1996, The Journal of clinical endocrinology and metabolism.

[34]  K. Herbst,et al.  Testosterone administration to normal men decreases truncal and total body fat , 1996 .

[35]  A. Matsumoto,et al.  Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. , 1996, The Journal of clinical endocrinology and metabolism.

[36]  I. Feuerstein,et al.  Very low high-density lipoproteins without coronary atherosclerosis , 1993, The Lancet.

[37]  E. Seeman,et al.  Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. , 1993, The Journal of clinical endocrinology and metabolism.

[38]  A. Matsumoto,et al.  Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. , 1993, The Journal of clinical endocrinology and metabolism.

[39]  E. Wallace,et al.  Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception. , 1993, International journal of andrology.

[40]  David Handelsman,et al.  Suppression of human spermatogenesis by testosterone implants. , 1992, The Journal of clinical endocrinology and metabolism.

[41]  S. Bhasin,et al.  Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. , 1992, The Journal of clinical endocrinology and metabolism.

[42]  J. Lindner,et al.  Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. , 1991, The Journal of clinical endocrinology and metabolism.

[43]  M. Dean London Perspective Manicures and Chablis but no extra NHS cash , 1990, The Lancet.

[44]  David Handelsman,et al.  Pharmacokinetics and pharmacodynamics of testosterone pellets in man. , 1990, The Journal of clinical endocrinology and metabolism.

[45]  J. Geelen,et al.  The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. , 1975, Acta endocrinologica.

[46]  Victor C. Strasburger,et al.  Contraception , 1924, The Indian Medical Gazette.

[47]  E. Nieschlag,et al.  Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. , 2001, The Journal of clinical endocrinology and metabolism.

[48]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[49]  Y. Gui,et al.  Inhibitine effects of sino-implant plus testosterone undecanoate (TU) on spermatogenesis in Chinese men. , 1999, Reproduction and contraception.

[50]  R. Balasubramanian,et al.  Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. , 1999, The Journal of clinical endocrinology and metabolism.

[51]  M. Pandian,et al.  A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. , 1992, The Journal of clinical endocrinology and metabolism.